Nerve Sheath Neoplasms - 25 Studies Found
Terminated |
: Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas : Neurofibroma : 2008-07-14 : Drug: LS11 LS11 will be given as a one-time IV infusion over 3-5 minutes. |
Terminated |
: First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas : Cutaneous Neurofibromas : 2009-06-15 : Procedure: Erbium-YAG laser vaporization spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequen |
Active, not recruiting |
: Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas :
: 2010-06-08 : Drug: Gleevec Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with |
Active, not recruiting |
: Study of PEG-Intron for Plexiform Neurofibromas : Plexiform Neurofibroma : 2006-11-02 : Drug: PEG-Intron |
Terminated |
: Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors : Malignant Peripheral Nerve Sheath Tumors : 2007-01-25 : Drug: imatinib mesylate |
Recruiting |
: Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors : Malignant Peripheral Nerve Sheath Tumors : 2017-04-13 |
Recruiting |
: Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas : Plexiform Neurofibromas : 2014-06-25 : Drug: Imatinib Mesylate oral administration Other Na |
Terminated |
: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) : Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 : 2011-05-27 : Drug: Everolimus (RAD001) oral daily dosing of tablet starting with 2.5 mg |
Recruiting |
: A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery : Malignant Peripheral Nerve Sheath Tumour (MPNST) : 2016-02-04 : Drug: Pembrolizumab Other Name: Keytruda |
Completed |
: Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 :
: 2008-03-27 : Drug: Ranibizumab Given as an injection into three cutaneous neurofibromas on day 1 of the study treatme |